Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $0.00, down 6.25% on the session, giving a market capitalisation of $127,117. On trailing twelve-month figures it carries a trailing P/E of 0.00, a net margin of 0.0%. Its beta of 1.92 implies it has historically moved more than the broad market.
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Petros Pharmaceuticals, Inc. is most often compared with the following Healthcare names: